Lanreotide Long-Acting Aqueous Gel clinical trials
How each study uses Lanreotide Long-Acting Aqueous Gel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 5
Ipsen (8) · Sheba Medical Center (1) · University Hospital, Ghent (1) · Universitaire Ziekenhuizen KU Leuven (1) · Federico II University (1) · Radboud University Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Lanreotide Long-Acting Aqueous Gel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedPhase 3IpsenNCT04852679Written as Lanreotide autogelHow we know
- Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of InfancyCompletedPhase 4Sheba Medical CenterNCT01070758Written as Lanreotide autogelHow we know
- Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedPhase 3IpsenNCT00690898Written as Lanreotide autogel 120 mgHow we know
- Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgCompletedPhase 2IpsenNCT02651987Written as Lanreotide autogel 120 mgHow we know
- Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid SyndromeTerminatedPhase 3IpsenNCT00092287Written as lanreotide Autogel (somatostatin analogue)How we know
- Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETCompletedPhase 2IpsenNCT02231762Written as Lanreotide Autogel 120 mgHow we know
- Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal ObstructionCompletedPhase 2IpsenNCT02275338Written as Lanreotide AutogelHow we know
- Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedPhase 4IpsenNCT00701363Written as Lanreotide Autogel 120 mgHow we know
- Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyCompletedPhase 3IpsenNCT02493517Written as Lanreotide Autogel®How we know
- Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for RectumcarcinomaCompletedPhase 3University Hospital, GhentNCT01372007Written as Lanreotide Autogel 120mgHow we know
- Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver DiseaseCompletedPhase 2/3Universitaire Ziekenhuizen KU LeuvenNCT01315795Written as Lanreotide Autogel 90 mg and 120 mgHow we know
- Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedPhase 4Federico II UniversityNCT00627796Written as Lanreotide-Autogel 120 mgHow we know
- Treatment of the Dumping Syndrome With Lanreotide Autogel®Status unknownPhase 4Radboud University Medical CenterNCT00543179Written as Somatuline (Lanreotide Autogel®)How we know